Prothena Corp Public Ltd Co PRTA
Prothena Corp Public Ltd Co (Nasdaq: PRTA) is a CNS/neurology/psychiatry drug developer. Its lead program, PRX012, is in Phase 1 for Alzheimer's disease.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PRX012 | Alzheimer's disease (anti-Abeta, subcutaneous); Phase 1 ASCENT program complete, partnership being explored | antibody | Phase 1 |
| PRX123 | Alzheimer's disease (dual Abeta-tau vaccine); IND cleared Jan 2024, partnership being explored | vaccine | Pre-clinical |
| PRX012-TfR | Alzheimer's disease | antibody | Pre-clinical |
| TDP-43 CYTOPE | ALS / TDP-43 proteinopathies | biologic-other | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.